Abiraterone Acetate, Micronized and Aripiprazole Injection: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Abiraterone Acetate, Micronized
Aripiprazole Injection
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse effects
Interaction Deep Dive
Abiraterone acetate is a moderate CYP2D6 inhibitor. Coadministration of abiraterone with CYP2D6 substrates increases the concentration of CYP2D6 substrates, which may increase the risk of adverse reactions related to these substrates. When abiraterone acetate (1000 mg/day) and predniSONE were administered with dextromethorphan (30 mg), the dextromethorphan Cmax and AUC were increased 2.8-fold and 2.9-fold, respectively. Avoid coadministration for which minimal changes in concentration may lead to serious toxicities. If alternative treatments cannot be used, consider a dose reduction of the concomitant CYP2D6 substrate drug1.
Why it happens (mechanism)
Inhibition of CYP2D6-substrate metabolism by abiraterone acetate
Literature reports
1 report — tap to read
a) The Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively when dextromethorphan 30 mg was given with abiraterone acetate 1000 mg daily (plus predniSONE). The AUC for dextrorphan, the active metabolite of dextromethorphan, increased approximately 1.3-fold 1.
Common questions
Can I take Abiraterone Acetate, Micronized and Aripiprazole Injection together?
Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse effects Always confirm with your pharmacist or prescriber before making any change.
How serious is the Abiraterone Acetate, Micronized and Aripiprazole Injection interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Abiraterone Acetate, Micronized or Aripiprazole Injection need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: AKEEGA(TM) oral tablets, niraparib, abiraterone acetate oral tablets. Janssen Biotech, Inc. (per FDA), Horsham, PA, 2023. DailyMed
Keep reading about Abiraterone Acetate, Micronized
Keep reading about Aripiprazole Injection
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist